

DMDS offer Quiklase DUAL the first dual wavelengths laser

On December 18, 2007 Dental and Medical history was made when the United States Food and Drug Administration cleared a revolutionary Dual Wavelength laser for use in soft tissue dental surgery and tooth whitening under the 510(k) number K072995.

The concept of using Dual wavelength simultaneously was the brain child of inventor Calvin Ostler. He reasoned that the combination of a short wavelength which provides relatively superior coagulation results and a longer wavelength which provides relatively superior (ablation) tissue removal would produce beneficial effects never produced or witnessed before.

Mr Ostler and his colleagues produced and tested several prototypes and submitted an application to the United States Food and Drug Administration on October 22, 2007 for pre-market clearance of this Dual wavelength laser. On November 2, 2007 the United States Food and Drug Administration validated Mr. Ostler's belief that combined effects were unknown previously by rejecting the submission unless further studies were conducted. The United States Food and Drug Administration in the notice to Mr. Ostler dated November 2, 2007 stated:

“... Since the ratio can change between the two wavelengths and there is no predicate that uses two wavelengths simultaneously for this indication, please provide:

- A. Histological data showing the depth and width of penetration, zone of coagulation/tissue necrosis for a range of the wattage used for the dual wavelength.
- B. Histological data showing the depth and width of penetration, zone of coagulation/tissue necrosis for this combined wavelength (810nm and 980nm) compared to the individual 810nm wavelength and 980nm wavelength.”

Mr. Ostler and his colleagues conducted the in depth study with astonishing results. Combining the Dual wavelengths simultaneously produced tissue effects not possible to achieve with a single wavelength and histologically visible effects that are brand new to laser surgery. The results of the study were forwarded to the United States Food and Drug Administration who received the results on December 5, 2007.

The results were so conclusive that clearance was granted less than two weeks later.

The Dual wavelength laser represents the cutting edge in soft tissue surgery and is revolutionising Dental Surgery, Join the revolution Call DMDS +44 1227 780009

